المؤلفون: A. Sokolova A., A. Skripka I., I. Ivanov I., V. Kogay V., A. Listratov I., A. Gindis A., D. Napalkov A., А. Соколова А., А. Скрипка И., И. Иванов И., В. Когай В., А. Листратов И., А. Гиндис А., Д. Напалков А.

المساهمون: The study was performed with the support of the Sechenov University, Исследование проведено при поддержке Сеченовского Университета

المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 3 (2021); 423-428 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 3 (2021); 423-428 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: albumin to creatinine ratio, chronic kidney disease, atrial fibrillation, diabetes mellitus, albuminuria, альбумин-креатининовое отношение, хроническая болезнь почек, фибрилляция предсердий, сахарный диабет, альбуминурия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2499/2179; https://www.rpcardio.com/jour/article/view/2499/2180; Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.; Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363-9. DOI:10.1161/CIRCULATIONAHA.108.816082.; Bansal N, Zelnick LR, Alonso A, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol CJASN. 2017;12(9):1386-98. DOI:10.2215/CJN.01860217.; Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. DOI:10.1016/j.kint.2020.06.019.; Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol JASN. 2009;20(4):705-11. DOI:10.1681/ASN.2007111207.; Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: Prevention and management. J Res Med Sci Off J Isfahan Univ Med Sci. 2015;20(11):1112-20. DOI:10.4103/1735-1995.172845.; Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157(5):805-10. DOI:10.1016/j.ahj.2009.02.005.; Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-93. DOI:10.1016/j.jacc.2015.03.577.; Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet Lond Engl. 2010;375(9731):2073-81. DOI:10.1016/S0140-6736(10)60674-5.; Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331-40. DOI:10.1038/ki.2010.550.; van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52. DOI:10.1038/ki.2010.536.; Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Ann Clin Biochem. 2009;46(Pt 3):205-17. DOI:10.1258/acb.2009.009007.; Koopman MG, Krediet RT, Koomen GC, et al. Circadian rhythm of proteinuria: consequences of the use of urinary protein:creatinine ratios. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc. 1989;4(1):9-14.; Huan L, Yuezhong L, Chao W, HaiTao T. The urine albumin-to-creatinine ratio is a reliable indicator for evaluating complications of chronic kidney disease and progression in IgA nephropathy in China. Clin Sao Paulo Braz. 2016;71(5):243-250. DOI:10.6061/clinics/2016(05)01; Vart P, Scheven L, Lambers Heerspink HJ, et al. Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. Am J Kidney Dis Off J Natl Kidney Found. 2016;67(1):70-8. DOI:10.1053/j.ajkd.2015.05.025.; Medcalf EA, Newman DJ, Gorman EG, Price CP. Rapid, robust method for measuring low concentrations of albumin in urine. Clin Chem. 1990;36(3):446-9.; Sparkenbaugh EM, Chantrathammachart P, Mickelson J, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014;123(11):1747-56. DOI:10.1182/blood-2013-08-523936.; Lee I-O, Kratz MT, Schirmer SH, Baumhäkel M, Böhm M. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2012;343(2):253-7. DOI:10.1124/jpet.112.194837.; Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26(12):2787-92. DOI:10.1161/01.ATV.0000246797.05781.ad.; https://www.rpcardio.com/jour/article/view/2499

الاتاحة: https://www.rpcardio.com/jour/article/view/2499
https://doi.org/10.20996/1819-6446-2021-06-09

المؤلفون: A. Sokolova A., I. Goncharova V., A. Vedernikov A., N. Morozova S., D. Napalkov A., А. Соколова А., И. Гончарова В., А. Ведерников А., Н. Морозова С., Д. Напалков А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 332-340 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 332-340 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: atrial fibrillation, NT-proBNP, troponin Т, D-dimer, biomarkers, thromboembolic events, фибрилляция предсердий, тропонин Т, D-димер, биомаркеры, тромбоэмболические осложнения

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2444/2157; Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2018;138:421.DOI:10.1161/CIR.0000000000000549.; Conen D. Epidemiology of atrial fibrillation. Eur Heart J. 2018;39:1323-4. DOI:10.1093/eurheartj/ehy171.; Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. DOI:10.1016/j.rec.2016.11.033.; Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486. DOI:10.1161/JAHA.114.001486.; Andersson T, Magnuson A, Bryngelsson I, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34:1061-7. DOI:10.1093/eurheartj/ehs469; Voukalis C, Lip G, Shantsila E. Emerging tools for stroke prevention in atrial fibrillation. EBioMedicine 2016;4:26-39. DOI:10.1016/j.ebiom.2016.01.017.; Fuster V, Ryden L, Cannom D, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Circulation. 2006;114:e257-354. DOI:10.1016/j.jacc.2006.07.009.; Llombart V, Antolin-Fontes A, Bustamante A, et al. B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis. Pooled Data Meta-Analysis. Stroke. 2015;46:1187-95. DOI:10.1161/STROKEA-HA.114.008311.; Yang HL, Lin YP, Long Y, et al. Predicting cardioembolic stroke with the B-type natriuretic peptide test: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:1882-9. DOI:10.1016/j.jstroke-cerebrovasdis.2014.02.014.; Rodnguez-Yanez M, Sobrino T, Blanco M, et al. High serum levels of pro-brain natriuretic peptide (pro BNP) identify cardioembolic origin in undetermined stroke. Dis Markers. 2009;26:189-95. DOI:10.3233/DMA-2009-0630.; Svennberg E, Lindahl B, Berglund L, et al. NT-proBNP is a powerful predictor for incident atrial fibrillation — Validation of a multimarker approach. International Journal of Cardiology. 2016;223:74- 81. DOI:10.1016/j.ijcard.2016.08.001.; Yaghi S, Chang A, Ricci B, et al. Early Elevated Troponin Levels After Ischemic Stroke Suggests a Car-dioembolic Source. Stroke. 2018;49:121-6. DOI:10.1161/STROKEAHA.117.019395.; Scheitz J, Erdur H, Haeusler K, et al. Insular cortex lesions, cardiac troponin, and detection of previously unknown atrial fibrillation in acute ischemic stroke: insights from the troponin elevation in acute ischemic stroke study. Stroke. 2015;46:1196-201. DOI:10.1161/STROKEAHA.115.008681.; Yao T, Tian B, Li G, et al. Elevated plasma D-dimer levels are associated with short-term poor outcome in patients with acute ischemic stroke: a prospective, observational study. BMC Neurol. 2019;19:175. DOI:10.1186/s12883-019-1386-3.; Zhang J, Liu L, Tao J, et al. Prognostic role of early D-dimer level in patients with acute ischemic stroke. PLoS ONE. 2019;14(2):e0211458. DOI:10.1371/journal.pone.0211458.; Ponikowski P, Voors A, Anker S, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128.; Silvet H, Young-Xu Y, Walleigh D, et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. American Journal of Cardiology. 2003;92(9):1124-7. DOI:10.4065/80.8.1029.; Breidthardt T, Noveanu M, Cayir S, et al. The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. International Journal of Cardiology. 2009;136(2):193- 9. DOI:10.1016/j.ijcard.2008.04.045.; Goetze J, Friis-Hansen L, Rehfeld J, et al. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006;27(14):1648-50. DOI:10.1093/eurheartj/ehl109.; Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation. Circulation. 2012;125(13):1605-16. DOI:10.1161/CIRCULATIONAHA.111.038729.; Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-Btype natriuretic peptide for risk assessment in patients with atrial fibrillation. JACC. 2013;;61(22):2274-84. DOI:10.1016/j.jacc.2012.11.082.; Dudink EA, Weijs B, Tull S, et al. The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. Journal of Atrial Fibrillation. 2018;11(4):2058. DOI:10.4022/jafib.2058.; Holl MJ, van den Bos EJ, van Domburg RT, et al. NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department. Clin Cardiol. 2018;41:400-5. DOI:10.1002/clc.22883.; Sharma S, Jackson PG, Makan J. Cardiac troponins. Journal of Clinical Pathology. 2004;57(10):1025- 6. DOI:10.1136/jcp.2003.015420.; Maynard SJ, Menown I, Adgey A. Troponin T or troponin I as cardiac markers in ischaemic heart disease. Heart. 2000;83(4):371-3. DOI:10.1177/0192623316668276.; Redfearn DP, Ratib K, Marshall HJ, et al. Supraventricular tachycardia promotes release of troponin I in patients with normal coronary arteries. Int J Cardiol. 2005;102(3):521-2. DOI:10.1016/j.ij-card.2004.05.076.; Awke J, Halfor B, Kim E, et al. A review of cardiac and non-cardiac causes of troponin elevation and clinical relevance part I: cardiac causes. Cardiol Curr Res. 2017;(10):3. DOI:10.15406/jccr.2018.11.00360.; Roldan V, Marin F, D^az J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012;10(8):1500-7. DOI:10.1111/j.1538-7836.2012.04812.x.; Fan Y, Zhao X, Li X, et al. Cardiac troponin and adverse outcomes in atrial fibrillation: A metaanalysis. Clinica Chimica Acta. 2018;477:48-52. DOI:10.1016/j.cca.2017.11.040.; Stoyanov KM, Giannitsis E, Biener M, et al. Prognostic value of elevated high-sensitivity cardiac troponin T in patients admitted to an emergency department with atrial fibrillation. Europace. 2018;20(4):582-8. DOI:10.1093/europace/eux063.; Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55:2225-31. DOI:10.1016/j.jacc.2009.12.049.; Mahe I, Bergmann JF, Chassany O, et al. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thromb Res. 2012;129:693-9. DOI:10.1016/j.thromres.2011.08.014.; Li-Rui Y, Mei T. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients. Medicine 2018;97(43):e12622. DOI:10.1097/MD.0000000000012622.; Paulin BK, Cedric KK, Tamomh AG, Hui YD. Assessment of cardiac biomarkers (troponin, B-type natriuretic peptide, and D-dimer) in patients with non-valvular atrial fibrillation and stroke. Int J Health Sci (Qassim). 2019;13(6):3-12. PMID: 31745392; PMCID: PMC6852499.; Hijazi Z, Lindback J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke risk score:A biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582- 90. DOI:10.1093/eurheartj/ehw054.; Yucel O, Yucel H, Zorlu A. D-dimer is a predictor of cardiovascular death, and new-onset atrial fibrillation in patients with systolic heart failure. Int J Cardiol. 2017;247:39. DOI:10.1536/ihj.18-237.; Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, et al. Long-term stroke risk prediction in patients with atrial fibrillation: Comparison of the ABC-stroke and CHA2DS2-VASc scores. J Am Heart Assoc. 2017;6:e006490. DOI:DOI:10.1161/JAHA.117.006490.; https://www.rpcardio.com/jour/article/view/2444

الاتاحة: https://www.rpcardio.com/jour/article/view/2444
https://doi.org/10.20996/1819-6446-2021-04-14

المؤلفون: B. Tatarsky A., N. Kazennova V., D. Napalkov A., Б. Татарский А., Н. Казеннова В., Д. Напалков А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 2 (2020); 301-306 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 2 (2020); 301-306 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: dabigatran, rivaroxaban, apixaban, myocardial infarction, atrial fibrillation, дабигатран, ривароксабан, апиксабан, инфаркт миокарда, фибрилляция предсердий

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2168/1968; Connolly S., Ezekowitz M., Yusuf S., et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361:1139-51. DOI:10.1056/NEJMoa0905561.; Patel M., Mahaffey K., Garg J., et al. Rivaroxaban versus Warfarin in Nonval-vular Atrial Fibrillation. N Engl J Med 2011;365:883-89. DOI:10.1056/NEJMoa1009638.; Granger C., Alexander J., McMurray J. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011;365:981-92. DOI:10.1056/NEJMoa1107039.; Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104. DOI:10.1056/NEJMoa1310907; Kirchhof P., Benussi Si., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. DOI:10.1093/eurheartj/e.; Banerjee A., Lane D.A., Torp-Pedersen C., et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107:584-89. DOI:10.1160/TH11-11-0784.; Pisters R., Nieuwlaat R., Lane D., et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost. 2013;109:328-36. DOI:10.1160/TH12-08-0539.; Soliman E.Z., Safford M.M., Muntner P., et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014;174:107-14. DOI:10.1001/jamainternmed.2013.11912.; Violi F., Soliman E.Z., Pignatelli P., Pastori D. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc. 2016;5:e003347. DOI:10.1161/JAHA.116.003347.; Kralev S., Schneider K., Lang S., et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PloS One. 2011;6:e24964. DOI:10.1371/journal.pone.0024964.; Lee C.J.Y., Pallisgaard J.L., Olesen J.B., et al. Antithrombotic therapy and first myocardial infarction in patients with atrial fibrillation. J Am Coll Cardiol. 2017;69:2901-9. DOI:10.1016/j.jacc.2017.04.033.; Hohnloser S.H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669-76. DOI:10.1161/CIRCULATIONAHA.111.055970.; Uchino K., Hernandez A.V. Dabigatran Association With Higher Risk of Acute Coronary Events: Meta-analysis of Noninferiority Randomized Controlled Trials. Arch Intern Med. 2012;172:397-402. DOI:10.1001/archinternmed.2011.1666.; Mak K.H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012,2:e001592. DOI:10.1136/bmjopen-2012-001592.; Douxfils J., Buckinx F., Mullier F., et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and metaanalysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000515. DOI:10.1161/JAHA.113.000515.; Larsen T.B., Rasmussen L.H., Skjoth F., et al. Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation. J Am Coll Cardiol. 2013;61(22):2264-73. DOI:10.1016/j.jacc.2013.03.020.; O’Riordan M. Two new analyses link dabigatran to MI risk. Medscape. [cited by Jul 10, 2019]. Available from: www.medscape.com/viewarticle/807621.; Sipahi I., Celik S., Akyol A. Letter to the editor for «Efficacy and safety of dabigatran etexilate and warfarin in «real world» patients with atrial fibrillation» by Larsen et al. Am Coll Cardiol. 2013;62(10):945-6. DOI:10.1016/j.jacc.2013.03.020.; Artang R., Rome E., Nielsen J.D., Vidaillet H.J. Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors. Am J Cardiol. 2013;112(12):1973-9 . DOI:10.1016/j.amjcard.2013.08.027.; Dale B., Eikelboom J.W., Weitz J.I., et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis. 2013;35(2):295-301. DOI:10.1007/s11239-012-0857-9.; Lip G.Y.H., Lane D.A. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med. 2010;123(9):785-9. DOI:10.1016/j.amjmed.2010.01.031.; Giglio A.F., Basile E., Santangeli P., et al. Increased risk of myocardial infarction with dabigatran: Fact or fiction? Journal of Cardiovascular Medicine. 2014;15:19-26. DOI:10.1016/j.pan.2015.03.007.; FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. [cited by Jul 10, 2019]. Available from: http://www.fda.gov/drugs/drugsafety/ucm396470.htm.; Nazarian R.M., Van Cott E.M., Zembowicz A., Duncan L.M. Warfarin-induced skin necrosis. Am Acad Dermatol. 2009;1:325-32. DOI:10.1016/j.jaad.2008.12.039.; Go A.S., Singer D.E., Toh S., et al. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017;167(12):845-854. DOI:10.7326/M16-1157; Stolk L.M., de Vries F., Ebbelaar C., et al. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol. 2017;83(8):1835-43. DOI:10.1111/bcp.13264.; Darwiche W., Bejan-Angoulvant T., Angoulvant D., et al. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists Meta-analysis of observational analyses. Thromb Haemost. 2016;116:1150-8. DOI:10.1160/TH16-06-0483.; Wei A.H., Gu Z.C., Zhang C., et al. Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580000 patients from integrating randomized controlled trials and real-world studies. Int J Cardiol. 2018;267:1-7. DOI:10.1016/j.ijcard.2018.05.048.; Lee C.J.Y., Gerds T.A., Carlson N., et al. Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:17-26 . DOI:10.1016/j.jacc.2018.04.036.; Lauffenberger J.C., Farley J.F., Gehi A.K., et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4:e001798. DOI:10.1161/JAHA.115.001798.; Graham D.J., Reichman M.E., Wernecke M., et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157-64. DOI:10.1161/CIRCULATIONAHA.114.012061.; Devereaux P.J., Duceppe E., Guyatt G., et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;39:2325-34. DOI:10.1016/S0140-6736(18)30832-8.; https://www.rpcardio.com/jour/article/view/2168

الاتاحة: https://www.rpcardio.com/jour/article/view/2168
https://doi.org/10.20996/1819-6446-2020-04-17

المؤلفون: K. Mirzaev B., D. Ivashchenko V., I. Volodin V., E. Grishina A., K. Akmalova A., A. Kachanova A., A. Skripka I., R. Minnigulov M., T. Morozova E., O. Baturina A., A. Levanov N., T. Shelekhova V., A. Kalinkin I., D. Napalkov A., A. Sokolova A., D. Andreev A., I. Sychev N., P. Bochkov O., D. Sychev A., К. Мирзаев Б., Д. Иващенко В., И. Володин В., Е. Гришина А., К. Акмалова А., А. Качанова А., А. Скрипка И., Р. Миннигулов М., Т. Морозова Е., О. Батурина А., А. Леванов Н., Т. Шелехова В., А. Калинкин И., Д. Напалков А., А. Соколова А., Д. Андреев А., И. Сычев Н., П. Бочков А., Д. Сычев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 5 (2020); 670-677 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 5 (2020); 670-677 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: dabigatran, rivaroxaban, pharmacogenetics, direct oral anticoagulants, sequencing, personalized medicine, дабигатран, ривароксабан, фармакогенетика, прямые оральные антикоагулянты, секвенирование, персонализированная медицина

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2288/2044; https://www.rpcardio.com/jour/article/view/2288/2069; Alalwan A.A., Voils S.A., Hartzema A.G. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237-44. DOI:10.2146/ajhp160756.; Loo S.Y., Dell'Aniello S., Huiart L., et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096-106. DOI:10.1111/bcp.13299.; Ziakas P.D., Kourbeti I.S., Poulou L.S., et al. Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect". PLoS One. 2018;13(6):e0198674. DOI:10.1371/journal.pone.0198674.; Philippidis A. Top 15 Best-Selling Drugs of 2018: Sales for most treatments grow year-over-year despite concerns over rising prices. Genetic Engineering & Biotechnology News. 2019 39(4):16-7.; Alfirevic A., Downing J., Daras K., et al. Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. BMJ Open. 2020;10(5):e033357. DOI:10.1136/bmjopen-2019-033357.; Ragia G., Manolopoulos V.G. Pharmacogenomics of anticoagulation therapy: the last 10 years. Pharmacogenomics. 2019;20(16):1113-7. DOI:10.2217/pgs-2019-0149.; Kanuri S.H., Kreutz R.P. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. J Pers Med. 2019;9(1):7. DOI:10.3390/jpm9010007.; Whirl-Carrillo M., McDonagh E.M., Hebert J.M., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-7. DOI:10.1038/clpt.2012.96.; Государственный реестр лекарственных средств [цитировано 20.07.2020. Доступно на: https://grls.rosminzdrav.ru/Default.aspx.; Gong I.Y., Kim R.B. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 Suppl):S24-S33. DOI:10.1016/j.cjca.2013.04.002.; Genome Aggregation Database [cited by Jul 20, 2020]. Available from: https://gnomad.broadinstitute.org.; Moner-Banet T., Alberio L., Bart P.A. Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature. Hamostaseologie. 2020;40(2):184-200. DOI:10.1055/a-1113-0655.; Shi J., Wang X., Nguyen J.H., et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76-84. DOI:10.1016/j.bcp.2016.09.003.; Paré G., Eriksson N., Lehr T., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404-12. DOI:10.1161/CIRCULATIONAHA.112.001233.; Dimatteo C., D'Andrea G., Vecchione G., et al. Pharmacogenetics of dabigatran etexilateinterindividual variability. Thromb Res. 2016;144:1-5. DOI:10.1016/j.thromres.2016.05.025.; Sychev D.A., Levanov A.N., Shelekhova T.V., et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [published correction appears in Pharmacogenomics Pers Med. 2018 Sep 26;11:167]. Pharmacogenomics Pers Med. 2018;11:127-37. DOI:10.2147/PGPM.S169277.; Gouin-Thibault I., Delavenne X., Blanchard A., et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-83. DOI:10.1111/jth.13577.; Sánchez Pascua T. Carboxylesterase 1 genetic variability, expression and potential for drug-drug interations. Diss. University of Liverpool, 2014 [cited by Jul 20, 2020]. Available from: https://livrepository.liverpool.ac.uk/2006752/1/SanchezTer_Sep2014_2006752.pdf.; Lorenzini K.I, Daali Y., Fontana P., et al. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7:494. DOI:10.3389/fphar.2016.00494.; Sennesael A.L., Larock A.S., Douxfils J., et al. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018;16:28. DOI:10.1186/s12959-018-0183-3.; https://www.rpcardio.com/jour/article/view/2288

الاتاحة: https://www.rpcardio.com/jour/article/view/2288
https://doi.org/10.20996/1819-6446-2020-10-05

المؤلفون: D. Napalkov A., Д. Напалков А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 15, No 6 (2019); 779-788 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 6 (2019); 779-788 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: hypertension, target blood pressure, fixed combinations, perindopril, epidemiology, артериальная гипертензия, целевое артериальное давление, фиксированные комбинации, периндоприл, эпидемиология

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2068/1883; Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;00:1-98. DOI:10.1093/eurheartj/ehy339.; Шальнова С.А., Баланова Ю.А., Константинов В.В., и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский Кардиологический Журнал. 2006;(4):45-50. DOI:10.15829/1560-4071-2006-445-50.; Бадин Ю.В., Фомин И.В., Беленков Ю.Н., и др. ЭПОХА-АГ 1998–2017 гг.: динамика распространенности, информированности об артериальной гипертонии, охвате терапией и эффективного контроля артериального давления в Европейской части РФ. Кардиология. 2019;59(1S):34-42. DOI:10.18087/cardio.2445.; Драпкина О.М. Комбинированная терапия пациентов высокого риска в условиях реальной клинической практики. Результаты исследования СИНЕРГИЯ. Часть 1. Антигипертензивная ветвь. Рациональная Фармакотерапия в Кардиологии. 2017;13(2):15563. DOI:10.20996/1819-6446-2017-13-2-155-163.; Rea F., Corrao G., Merlino L., Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654-61. DOI:10.1093/eurheartj/ehy420.; Cuende J.I., Cuende N., Calaveras-Lagartos J. How to calculate vascular age with the SCOREproject scales: a new method of cardiovascularrisk evaluation. Eur Heart J. 2010;31:2351-8. DOI:10.1093/eurheartj/ehq205.; https://www.rpcardio.com/jour/article/view/2068

الاتاحة: https://www.rpcardio.com/jour/article/view/2068
https://doi.org/10.20996/1819-6446-2019-15-6-779-788

المؤلفون: A. Skripka I., P. Bochkov O., K. Akmalova A., R. Shevchenko V., P. Krupenin M., V. Kogay V., A. Listratov I., A. Krainyaya S., D. Napalkov A., O. Gurinovich S., A. Sokolova A., V. Fomin V., D. Sychev A., А. Скрипка И., П. Бочков О., К. Акмалова А., Р. Шевченко В., П. Крупенин М., В. Когай В., А. Листратов И., А. Крайняя С., Д. Напалков А., О. Гуринович С., А. Соколова А., В. Фомин В., Д. Сычев А.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2019); 65-73 ; Медицинский Совет; № 21 (2019); 65-73 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-21

مصطلحات موضوعية: DOAC, dabigatran, atrial fibrillation, chronic kidney disease, hemorrhagic events, ABCB1, CES1, rs1045642, rs2244613, rs4148738, pharmacokinetics, pharmacogenetics, прямые оральные антикоагулянты, дабигатран, фибрилляция предсердий, хроническая болезнь почек, геморрагические события, фармакогенетика, фармакокинетика

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5476/4995; Márcio Galindo Kiuchi. Atrial fibrillation and chronic kidney disease: A bad combination. Kidney Research and Clinical Practice. 2018;37(2):103-105. doi:10.23876/j.krcp.2018.37.2.103.; Olesen J.B., Lip G.Y.H. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635. doi:10.1056/NEJMoa1105594.; KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011). 2018;8(3):91-165. doi: 0.1016/j.kisu.2018.06.001.; Stangier J., Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost/Hemost. 2009;1(15): 9S-16S. doi:10.1177/1076029609343004.; Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, singlecentre study. Clin Pharmacokinet. 2010;49(4):259-68. doi:10.2165/11318170-000000000-00000.; Ezekowitz M.D., Connolly S., Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805–10. doi:10.1016/j.ahj.2009.02.005.; Pare G. et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404–1412. doi:10.1161/CIRCULATIONAHA.112.001233.; van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., Clemens A. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127. doi:10.1160/TH09-11-0758.; Rodeghiero F., Tosetto A., Abshire T., Arnold D.M., Coller B., James P., Neunert C., Lillicrap D. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–5. doi:10.1111/j.1538-7836.2010.03975.x; https://www.med-sovet.pro/jour/article/view/5476

الاتاحة: https://www.med-sovet.pro/jour/article/view/5476
https://doi.org/10.21518/2079-701X-2019-21-65-73

المؤلفون: D. Napalkov A., A. Sokolova A., Д. Напалков А., А. Соколова А.

المساهمون: This publication was prepared with the support of Bayer., Публикация подготовлена при поддержке компании АО «Байер».

المصدر: Rational Pharmacotherapy in Cardiology; Vol 15, No 4 (2019); 553-557 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 4 (2019); 553-557 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2019-15-4

مصطلحات موضوعية: atrial fibrillation, elderly, rivaroxaban, warfarin, safety, фибрилляция предсердий, пожилой возраст, ривароксабан, варфарин, безопасность

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2009/1854; Krijthe B.P., Kunst A., Benjamin E.J., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746-51. DOI:10.1093/eurheartj/eht280.; Boriani G., Proietti M., Laroche C., et al. on behalf of the EORP-AF Long-Term General Registry Investigators. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20:747-57. DOI:10.1093/europace/eux301.; Proietti M., Laroche C., Opolski G., et al. on behalf of the AF Gen Pilot Investigators. “Real-world” atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace. 2017;19:722-33. DOI:10.1093/europace/euw112.; Hess P.L., Kim S., Fonarow G.C., et al. on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Patients and Investigators. Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. The American Journal of Medicine. 2017;130:449-56. DOI:10.1016/j.amjmed.2016.11.001.; Zoppellaro G., Zanella L., Denas G., Genet al. Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity scorematched cohort study. International Journal of Cardiology. 2018;265:103-7. DOI:10.1016/j.ijcard.2018.04.117.; Rutherford O.C.W., Jonasson C., Ghanima W., et al. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart. 2018;5:e000931. DOI:10.1136/openhrt2018-000931.; Khan F., Huang H., Datta Y.H. Direct Oral Anticoagulant Use and the Incidence of Bleeding in the Very Elderly With Atrial Fibrillation. J Thromb Thrombolysis. 2016;42(4):573-8. DOI:10.1007/s11239016-1410-z.; Kim H.M., Choi E.K., Park C.S., et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with nonvalvular atrial fibrillation. PLoS ONE. 2019;14(3):e0211766. DOI:10.1371/journal.pone.0211766.; Monelli M., Molteni M., Cassetti G., et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study data from the REGIstry of patients on Non-vitamin Koral Anticoagulants (REGINA). Vascular Health and Risk Management. 2019;15:19-25.; Halperin J.L., Hankey G.J., Wojdyla D.M., et al.; ROCKET AF Steering Committee and Investigators. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130:138-46. DOI:10.1161/CIRCULATIONAHA.113.005008; Kirchhof P., Radaideh G., Kim Y.H., et al. Global XANTUS program Investigators. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018;72(2):141-53. DOI:10.1016/j.jacc.2018.04.058.; https://www.rpcardio.com/jour/article/view/2009

الاتاحة: https://www.rpcardio.com/jour/article/view/2009
https://doi.org/10.20996/1819-6446-2019-15-4-553-557

المؤلفون: B. Tatarsky A., N. Kazennova V., D. Napalkov A., Б. Татарский А., Н. Казеннова В., Д. Напалков А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 15, No 5 (2019); 675-680 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 5 (2019); 675-680 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: drug hepatotoxicity, rivaroxaban, dabigatran, apixaban, atrial fibrillation, randomized trials, лекарственная гепатотоксичность, ривароксабан, дабигатран, апиксабан, фибрилляция предсердий, рандомизированные исследования

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2038/1868; Harder S., Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69:1617-33. DOI:10.1007/s00228-013-1510-z.; Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of druginduced liver injury. World J Gastroenterol. 2008;14(44):6774-85. DOI:10.3748/wjg.14.6774.; Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-9. DOI:10.1056/NEJMra052270.; Lauschke V., Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016;17:1714. DOI:10.3390/ijms17101714.; Goldberg D.S., Forde K.A., Carbonari D.M., et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology. 2015;148:1353-61. DOI:10.1053/j.gastro.2015.02.050.; Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6. DOI:10.1016/0168-8278(90)90124-A.; Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in druginduced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15. DOI:10.1038/clpt.2011.; Liakoni E., Ratz Bravo A.E., Krahenbuhl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015;38:711-20. DOI:10.1007/s40264-015-0317-5.; Agnelli G., Eriksson B.I., Cohen A.T., et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123:488-97. DOI:10.1016/j.thromres.2008.02.017.; Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80. DOI:10.1016/S0140-6736(09)60734-0.; Watkins P.B., Desai M., Berkowitz S.D., et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34:243-52. DOI:10.2165/11586600-000000000-00000.; Caldeira D., Barra M., Santos A.T., et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100:550-6. DOI:10.1136/heartjnl-2013-305288.; Alonso A., MacLehose R.F., Chen L.Y., et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart. 2017;103:834-9. DOI:10.1136/heartjnl-2016-310586.; Raschi E., Poluzzi E., Koci A., et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80:285-93. DOI:10.1111/bcp.12611.; Licata A., Puccia F., Lombardo V., et al. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol. 2018;30(2):226-32. DOI:10.1097/MEG.0000000000001030.; Cordeanu M., Gaertner S., Bensalah N., et al. Rivaroxaban induced liver injury: a cholestatic pattern. Int J Cardiol. 2016;216:97-8. DOI:10.1016/j.ijcard.2016.04.063.; Lambert A., Cordeanu M., Gaertner S., et al. Rivaroxaban-induced liver injury: results from a venous thromboembolism registry. Int J Cardiol. 2015;191:265-6. DOI:10.1016/j.ijcard.2015.04.248.; Glenn K., Chen P., Musleh M., et al. A rare case of rivaroxaban causing delayed symptomatic hepatocellular injury and hyperbilirubinemia. Case Rep Gastrointest Med 2017; 2017: 5678187. DOI:10.1155/2017/5678187.; Baig M., Wool K.J., Halanych J.H., et al. Acute liver failure after initiation of rivaroxaban: a case report and review of the literature. N Am J Med Sci. 2015;7:407-10. DOI:10.4103/1947-2714.166221.; Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol. 2011;8:202-11. DOI:10.1038/nrgastro.2011.22.; Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95- 106. DOI:10.1016/j.mayocp.2013.09.016.; Godoy P., Hewitt N.J., Albrecht U., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87:1315-530. DOI:10.1007/s00204-013-1078-5.; Gong I.Y., Kim R.B. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24-33. DOI:10.1016/j.cjca.2013.04.002.; https://www.rpcardio.com/jour/article/view/2038

الاتاحة: https://www.rpcardio.com/jour/article/view/2038

المؤلفون: I. Daabul S., A. Sokolova A., I. Tsarev L., D. Napalkov A., V. Fomin V., И. Даабуль С., А. Соколова А., И. Царев Л., Д. Напалков А., В. Фомин В.

المصدر: Meditsinskiy sovet = Medical Council; № 5 (2019); 14-19 ; Медицинский Совет; № 5 (2019); 14-19 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-5

مصطلحات موضوعية: atrial fibrillation (AF), direct oral anticoagulants (DOACs), vitamin K antagonists (VKA), warfarin, dabigatran, rivaroxaban, apixaban, chronic kidney disease (CKD), фибрилляция предсердий (ФП), прямые оральные антикоагулянты (ПОАК), антагонисты витамина К (АВК), варфарин, дабигатран, ривароксабан, апиксабан, хроническая болезнь почек (ХБП)

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2909/2840; Olesen J.B. et al., Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-35.; Kirchhof P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016.; Hijazi Z. et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Longterm Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961-70.; Fox K.A. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94.; Hohnloser S.H. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-30.; Raccah B.H. et al. Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials. Chest. 2016;149(6):1516-24.; Wheeler D.S., Giugliano R.P., and Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost. 2016;14(3):461-7.; Factor XA – Inhibition in RENal Patients With Non-valvular Atrial Fibrillation – Observational Registry (XARENO). [cited 2019 18/02]; Available from: https://clinicaltrials.gov/ct2/ show/NCT02663076?cond = NCT02663076&rank = 1.; Dabigatran vs Warfarin in AF Patients With T2D and CKD (RE-ELECT). [cited 2019 18/02]; Available from: https://clinicaltrials.gov/ct2/ show/NCT03789695?cond = re-elect&rank = 1.; Böhm M. et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-93.; Hijazi Z. et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451-60.; Fumagalli S., Said S.A.M., Laroche C., Gabbai D., Marchionni N., Boriani G., Maggioni A.P., Popescu M.I., Rasmussen R.H., Crijns H.G.J.M., Lip G.Y.P. on behalf of the EORP-AF investigators. Agerelated differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. J Am Coll Cardiol EP. 2015;1:326–34. doi:10.1016/j.jacep.2015.02.019.; https://www.med-sovet.pro/jour/article/view/2909

الاتاحة: https://www.med-sovet.pro/jour/article/view/2909
https://doi.org/10.21518/2079-701X-2019-5-14-19

المؤلفون: D. Napalkov A., A. Sokolova A., Д. Напалков А., А. Соколова А.

المصدر: Meditsinskiy sovet = Medical Council; № 5 (2019); 54-59 ; Медицинский Совет; № 5 (2019); 54-59 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-5

مصطلحات موضوعية: adherence, compliance, arterial hypertension, dyslipidemia, lysinepril, prolonged action indapamide, amlodipine, rosuvastatin, приверженность, комплаенс, артериальная гипертензия, дислипидемия, лизиноприл, индапамид пролонгированного действия, амлодипин, розувастатин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2918/2849; Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Конради А.О., Либис Р.А., Минаков А.В., Недогода С.В., Ощепкова Е.В., Романчук С.А., Ротарь О.П., Трубачева И.А., Чазова И.Е., Шляхто Е.В. от имени участников исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14. (In Russ).; Tomaszewski M., White C., Patel P., Masca N., Damani R., Hepworth J., Samani N.J., Gupta P., Madira W., Stanley A., Williams B. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/ MS) urine analysis. Heart. 2014;100(11):855–861. doi:10.1136/heartjnl-2013-305063.; Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A., de Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S.E., Kreutz R., Laurent S., Lip G.Y.H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R.E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of ESC and ESH. Eur Heart J. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940.; Corrao G., Parodi A., Nicotra F., Zambon A., Merlino L., Cesana G., Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610– 618. doi:10.1097/HJH.0b013e328342ca97.; Burnier M., Wuerzner G., Struijker-Boudier H., Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–225. doi:10.1161/HYPERTENSIONAHA.113.00687.; Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–887. doi:10.1016/j. amjmed.2011.12.013.; Концевая А.В., Романенко Т.С., Выгодин В.А., Фитилев С.Б. Фармакоэпидемиология и эффективность антигипертензивной терапии в реальной практике специализированного кардиологического учреждения. Рациональная фармакотерапия в кардиологии. 2015;11(1):817.; Fung V., Graetz I., Reed M., Jaffe M.G. Patientreported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS ONE. 2018;13(2):e0191817. https://doi.org/10.1371/journal.pone.0191817.; Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5-22.; Карпов Ю.А. Исследование ТРИУМВИРАТ: снижение риска развития сердечно-сосудистых осложнений у больных артериальной гипертонией с помощью трехкомпонентной комбинации антигипертензивных и липидснижающих препаратов. Кардиология. 2015;55(9):10–15.; https://www.med-sovet.pro/jour/article/view/2918

الاتاحة: https://www.med-sovet.pro/jour/article/view/2918
https://doi.org/10.21518/2079-701X-2019-5-54-59

المؤلفون: D. Napalkov A., A. Sokolova A., M. Gabitova A., L. Uddin N., Д. Напалков А., А. Соколова А., М. Габитова А., Л. Уддин Н.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 14, No 5 (2018); 785-789 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 5 (2018); 785-789 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-5

مصطلحات موضوعية: atrial fibrillation, difficult patients, elderly, rivaroxaban, warfarin, фибрилляция предсердий, сложные пациенты, пожилые пациенты, ривароксабан, варфарин

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1769/1729; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. doi:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91. doi:10.1056/NEJMoa1009638.; Granger C.B., Alexander J.H., McMurray J.J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi:10.1056/NE-JMoa1107039.; Camm A.J., Fox K.A.A., Peterson E. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace. 2018;20(1):1-11. doi:10.1093/europace/eux086.; Steinberg B.A., Hellkamp A.S., Lokhnygina Y., et al. ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2015;36:288-96. doi:10.1093/eurheartj/ehu359.; Sherwood M.W., Nessel C.C., Hellcamp A.S., et al. Gastrointestinal Bleeding in Patients with Atrial Fibrillation Treated with Rivaroxaban or Warfarin. JACC. 2015;66(21):2271-81. doi:10.1016/j.jacc.2015.09.024.; Lopes R.D., Al-Khatib S.M., Wallentin L., et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012;380(9855):1749-58. doi:10.1016/S0140-6736(12)60986-6.; Eikelboom JW, Connolly SJ, Hart RG, et al. Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. JACC. 2013;62(10):900-8. doi:10.1016/j.jacc.2013.05.042.; Tamayo S.G., Simeone J.C., Nordstrom B.L., et al. Risk factors for major bleeding in rivaroxaban users with atrial fibrillation. J Am Coll Card. 2016;10(68):1143-9. doi:10.1016/j.jacc.2016.06.028.; (In Russ.) [Соколова А.А., Царев И.Л., Напалков Д.А., Сулимов В.А. Наблюдение за пациентами с фибрилляцией предсердий неклапанной этиологии в рамках работы кабинета контроля антикоагулянтной терапии: длительное эффективное и безопасное применение антикоагулянтов. Фарматека. 2016;6(319):45-50].; Yao X., Shah N.D., Sangaralingham L.R., et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients with Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69:2779-90. doi:10.1016/j.jacc.2017.03.600.; Nielsen P.B., Skjoth F., Sogaard M., et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. doi:10.1136/bmj.j510.; https://www.rpcardio.com/jour/article/view/1769

الاتاحة: https://www.rpcardio.com/jour/article/view/1769
https://doi.org/10.20996/1819-6446-2018-14-5-785-789

المؤلفون: I. Daaboul S., S. Koroleva Yu., A. Kudrjavtseva A., A. Sokolova A., D. Napalkov A., V. Fomin V., И. Даабуль С., С. Королева Ю., А. Кудрявцева А., А. Соколова А., Д. Напалков А., В. Фомин В.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 14, No 3 (2018); 350-355 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 3 (2018); 350-355 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-3

مصطلحات موضوعية: atrial fibrillation nonvalvular etiology, direct oral anticoagulants, apixaban, dabigatran, left atrial appendage thrombosis, фибрилляция предсердий неклапанной этиологии, прямые пероральные антикоагулянты, апиксабан, дабигатран, тромбоз ушка левого предсердия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1689/1651; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi:10.1056/NEJMoa1009638 .; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.; Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.; Elliott P.M., Anastasakis A., Borger M.A., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. EurHeartJ. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.; Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi:10.1093/europace/euv309.; MacIntyre C., Lakdawala N.K. Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2016;133(19): 1901-5. doi:10.1161/CIRCULATIONAHA.115.015085.; Guttmann O.P., Pavlou M., O'Mahony C., et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail. 2015;17(8):837-45. doi:10.1002/ejhf.316.; January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. doi:10.1161/CIR.0000000000000041.; Szegedi N., Gellér L., Tahin T., et al. Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy. Orv Hetil. 2016;157(4):154-6. doi:10.1556/650.2016.30350.; De Caterina R., Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017;106(8):565-572. doi:10.1007/s00392-017-1102-5.; Watanabe T., Shinoda Y., Ikeoka K., et al. Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation. Intern Med. 2017. 56(15):1977-80. doi:10.2169/internalmedicine.56.8508.; Al-Saady N.M., Obel O.A., Camm A.J. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999. 82(5):547-54. doi:10.1136/hrt.82.5.547.; Ellis K., Ziada K.M., Vivekananthan D., et al. Transthoracic echocardiographic predictors of left atrial appendage thrombus. Am J Cardiol. 2006. 97(3):421-5. doi:10.1016/j.amjcard.2005.08.065.; Tsai L.M., Lin L.J., Teng J.K., Chen J.H. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol. 1997;58(2):163-9. doi:10.1016/S016715273(96)02862-8.; Ayirala S., Kumar S., O'Sullivan D.M., Silverman D.I. Echocardiographic predictors of left atrial appendage thrombus formation. J Am Soc Echocardiogr. 2011. 24(5):499-505. doi:10.1016/j.echo.2011.02.010.; Nagarakanti R., Ezekowitz M.D., Oldgren J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011. 123(2):131-6. doi:10.1161/CIRCULATIONAHA.110.977546.; Flaker G., Lopes R.D., Al-Khatib S.M., et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-7. doi:10.1016/j.jacc.2013.09.062.; Piccini J.P., Stevens S.R., Lokhnygina Y., et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013. 61(19):1998-2006. doi:10.1016/j.jacc.2013.02.025.; Mitamura H., Nagai T., Watanabe A., et al. Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report. J Arrhythm. 2015;31(4):226-31. doi:10.1016/j.joa.2014.12.010.; Morita S., Ajiro Y., Uchida Y., Iwade K. Dabigatran for left atrial thrombus. Eur Heart J. 2013;34(35):2745. doi:10.1093/eurheartj/eht148.; Vidal A., Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34(4):545-7. doi:10.1007/s11239-012-0747-1.; Qazi A.H., Wimmer A.P., Huber K.C., et al. Resolution (and Late Recurrence) of WATCHMAN Device-Related Thrombus Following Treatment with Dabigatran. Echocardiography. 2016;33(5):7921795. doi:10.1111/echo.13174.; Tabata E., Yasaka M., Wakugawa Y., et al. Increase in the Size of an Intracardiac Thrombus during Dabigatran Therapy (110 mg b.i.d.) in an Acute Cardioembolic Stroke Patient. Cerebrovasc Dis Extra. 2013;3(1):78-80. doi:10.1159/000351137.; Wyrembak J., Campbell K.B., Steinberg B.A., et al. Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. Am J Cardiol. 2017;119(7):1017-1022. doi:10.1016/j.amjcard.2016.12.008.; Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360-420. doi:10.1093/europace/euq350.; Hammerstingl C., Pötzsch B., Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109(4):583-4. doi:10.1160/TH12-11-0821.; Dobashi S., Fujino T., Ikeda T. Use of apixaban for an elderly patient with left atrial thrombus. BMJ Case Rep. 2014. pii: bcr2014203870. 2014. doi:10.1136/bcr-2014-203870.; Kawakami T., Kobayakawa H., Ohno H., et al. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013. 11(1):26. doi:10.1186/1477-9560-11-26.; Takasugi J., Yamagami H., Okata T., et al. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis. 2013;36(4):322-3. doi:10.1159/000354315.; Vaquerizo B., Sami M. Left Atrial Appendage Thrombus Resolution with Reduced Dose Apixaban. J Atr Fibrillation. 2015;8(1):1182. doi:10.4022/jafib.1182.; Eftekhari A., Damgaard D., Grove E.L. Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus. Int J Cardiol. 2016;214:131-2. doi:10.1016/j.ijcard.2016.03.147.; Ohyagi M., Nakamura K., Watanabe M., Fujigasaki H. Embolic stroke during apixaban therapy for left atrial appendage thrombus. J Stroke Cerebrovasc Dis. 2015;24(4):e101-2. doi:10.1016/j.jstrokecerebrovasdis.2014.11.031.; Miwa Y., Minamishima T., Sato T., et al. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J Arrhythm. 2016;32(3):233-5. doi:10.1016/ j.joa.2016.01.009.; Koyama T., Otsuka Y., Kawahara M., et al. A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban. Clin Case Rep. 2017;5(5):711-3. doi:10.1002/ccr3.933.; Nagamoto Y., Shiomi T., Sadamatsu K. Thrombolytic action of dabigatran in patients with acute preexisting atrial thrombus. Europace. 2013;15(11):1608. doi:10.1093/europace/eut096.; Lee C.L., Wang H.H., Tsao H.M. The antithrombotic effect of dabigatran. Can J Cardiol. 2014;30(2):248.e1-2. doi:10.1016/j.cjca.2013.09.028.; Santangelo G., Ielasi A., Antonio Scopelliti P., et al. Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient. J Atr Fibrillation. 2016;9(4):1509. doi:10.4022/jafib.1509.; Li Y., Lin J., Peng C. Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review. Medicine (Baltimore). 2016;95(49):e5577. doi:10.1097/MD.0000000000005577.; Ferner M., Wachtlin D., Konrad T., et al. Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016;105(1):29-36. doi:10.1007/s00392-015-0883-7.; Lip G.Y., Hammerstingl C., Marin F., et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observationalregistry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126-34. doi:10.1016/j.ahj.2016.05.007.; Bernhardt P., Schmidt H., Hammerstingl C., et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94(6):801-4. doi:10.1016/j.amjcard.2004.06.010.; https://www.rpcardio.com/jour/article/view/1689

الاتاحة: https://www.rpcardio.com/jour/article/view/1689
https://doi.org/10.20996/1819-6446-2018-14-3-350-355

المؤلفون: D. Napalkov A., A. Sokolova A., Д. Напалков А., А. Соколова А.

المصدر: Meditsinskiy sovet = Medical Council; № 5 (2018); 70-74 ; Медицинский Совет; № 5 (2018); 70-74 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-5

مصطلحات موضوعية: atrial fibrillation, direct oral anticoagulants, elderly patient, thromboembolic complications, hemorrhagic complications, фибрилляция предсердий, прямые пероральные антикоагулянты, пожилой пациент, тромбоэмболические осложнения, геморрагические осложнения

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2360/2343; Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, Healey JS, Bell A, Pilote L, Andrade JG, Mitchell LB, Atzema C, Gladstone D, Sharma M, Verma S, Connolly S, Dorian P, Parkash R, Talajic M, Nattel S and Verma A for the CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. doi:10.1016/j.cjca.2016.07.591; Lip GYH, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJGM, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP and Boriani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EUROobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot Registry). Eur Heart J, 2014, 35: 3365-3376. doi:10.1093/eurheartj/ehu374.; Gomez-Outes A, Suarez-Gea ML, Garcia-Pinilla JM. Causes of death in atrial fibrillation: Challenges and opportunities. Trends Cardiovasc Med, 2017, 27(7): 494-503. doi:10.1016/j. tcm.2017.05.002.; Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2018, 39(3): 213-260. doi:10.1093/eurheartj/ehx419.; Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J, 2017 Mar 21, 38(12):852-859. doi:10.1093/eurheartj/ehv643.; Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med, 2016, 375(25): 2423-2434. doi:10.1056/ NEJMoa1611594.; Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators. Dual Anti thrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med, 2017, 377(16): 1513-1524. doi:10.1056/NEJMoa1708454.; Hutcherson TC, Cieri-Hutcherson NE, Bhatt R. Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis. P T, 2017, 42(11): 692–698.; Åsberg S1, Eriksson M, Henriksson KM, Terént A. Reduced risk of death with warfarin – results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke. Int J Stroke, 2013, 8(8): 689-95. doi:10.1111/j.1747-4949.2012.00855.; Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S, RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol, 2010, 9(12): 1157-1163. doi:10.1016/S1474-4422(10)70274-X.; Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361(12): 1139-51. doi:10.1056/NEJMoa0905561.; Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365(10): 883-91. doi:10.1056/ NEJMoa1009638.; Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365(11): 981-92. doi:10.1056/NEJMoa1107039.; Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation, 2014, 129(9): 961-70. doi:10.1161/ CIRCULATIONAHA.113.003628.; Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol, 2015, 65(23): 2481-93. doi:10.1016/j.jacc.2015.03.577.; Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol, 2015, 196: 127-31. doi:10.1016/j.ijcard.2015.05.141.; Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med, 2016 Nov 1, 176(11):1662-1671. doi:10.1001/jamainternmed.2016.5954.; Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs, 2017, 17(1): 37-47. doi:10.1007/s40256-016-0189-9.; https://www.med-sovet.pro/jour/article/view/2360

الاتاحة: https://www.med-sovet.pro/jour/article/view/2360
https://doi.org/10.21518/2079-701X-2018-5-70-74

المؤلفون: D. Napalkov А., A. Sokolova A., Д. Напалков А., А. Соколова А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 13, No 6 (2017); 851-855 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 6 (2017); 851-855 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-6

مصطلحات موضوعية: hypertension, ischemic heart disease, calcium channel blockers, amlodipine, артериальная гипертензия, ишемическая болезнь сердца, блокаторы кальциевых каналов, амлодипин

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1578/1587; Franklin S.S., Larson M.G., Khan S.A., et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103:1245-9. doi:10.1161/01.CIR.103.9.1245.; Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Int Med. 1992;152:56-64. doi:10.1001/archinte.1992.00400130082009.; Rosendorff C., Lackland D.T., Allison M., et al., on behalf of the American Heart Association, American College of Cardiology, and American Society of Hypertension. // Treatment of Hypertension in Patients With Coronary Artery Disease. Hypertension. 2015;65:1372-407. doi:10.1161/HYP.0000000000000018.; Nissen S.E., Tuzcu E.M., Libby P., et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT Study: a randomized controlled trial. JAMA. 2004;292:2217-25. doi:10.1001/jama.292.18.2217.; Rosendorff C. Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opin Pharmacother. 2003;4:1535-41. doi:10.1517/14656566.4.9.1535.; Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis. 2002; 165: 191-9. doi:10.1016/S00219150(01)00729-8.; Park S., Yan P., Cerezo C., Jeffers B.W. Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure. J Am Soc Hypertens. 2016;10(10):799-810. doi:10.1016/j.jash.2016.08.004.; Julius S., Kjeldsen S.E., Weber M., et al., VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31. doi:10.1016/S0140-6736(04)16451-9.; Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-35. doi:10.1016/S0140-6736(03)14739-3.; Wang J.G., Li Y., Franklin S.S., Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers. Hypertension. 2007;50:181-8. doi:10.1161/HYPERTENSIONAHA.107.089763; Lee S.A., Choi H.M., Park H.J., et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. Korean J Intern Med. 2014;29:315-324. doi:10.3904/kjim.2014.29.3.315.; Vlachopoulos C. Combination therapy in hypertension: from effects on arterial stiffness and central haemodynamics to cardiovascular benefits. Artery Research. 2016;14:27-35. doi:10.1016/j.ijcard.2016.11.149.; Bertrand M.E., Vlachopoulos C., Mourad J.J. Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril and amlodipine. Am J Cardiovasc Drugs. 2016;16(4):241-253. doi 10.1007/s40256-016-0175-2.; Bakris G., Briasoulis A., Dahlof B., et al., for the ACCOMPLISH Investigators. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. Am J Cardiol. 2013;112:255-9. doi:10.1016/j.amjcard.2013.03.026.; https://www.rpcardio.com/jour/article/view/1578

الاتاحة: https://www.rpcardio.com/jour/article/view/1578
https://doi.org/10.20996/1819-6446-2017-13-6-851-855

المؤلفون: A. Zhilenko V., A. Sokolova A., I. Tsarev L., D. Napalkov A., А. Жиленко В., А. Соколова А., И. Царев Л., Д. Напалков А.

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2017); 8-11 ; Медицинский Совет; № 11 (2017); 8-11 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-11

مصطلحات موضوعية: atrial fibrillation, direct oral anticoagulation, thromboembolic complications, bleeding risk, dabigatran, rivaroxaban, apixaban, фибрилляция предсердий, прямые пероральные антикоагулянты, тромбоэмболические осложнения, риск кровотечений, дабигатран, ривароксабан, апиксабан

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1906/1885; Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J, 2016. doi:10.1093/eurheartj/ehw210.; Gorst-Rasmussen A, Lip GYH and Larsen TB. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepid Drug Saf, 2016. doi:10.1002/pds.4034.; Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost, 2016, 19: 116(5).; Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs, 2016 Sep 14.; Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med, 2016 Oct 3. doi:10.1001/jamainternmed.2016.5954.; https://www.med-sovet.pro/jour/article/view/1906

الاتاحة: https://www.med-sovet.pro/jour/article/view/1906
https://doi.org/10.21518/2079-701X-2017-11-8-11

المؤلفون: I. Daabul S., A. Sokolova A., D. Napalkov A., И. Даабуль С., А. Соколова А., Д. Напалков А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 12, No 5 (2016); 595-602 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 5 (2016); 595-602 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-5

مصطلحات موضوعية: nonvalvular atrial fibrillation, chronic kidney disease, warfarin, direct oral anticoagulants, dabigatran, rivaroxaban, apixaban, renal arteries atherosclerosis, фибрилляция предсердий неклапанной этиологии, хроническая болезнь почек, варфарин, прямые пероральные антикоагулянты, дабигатран, ривароксабан, апиксабан, атеросклероз почечных артерий

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1342/1385; Zoni-Berisso M., Lercari F., Carazza T., et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-20.; National guidelines on the diagnosis and treatment of atrial fibrillation (2012). Available at: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Retrieved 09/18/2016. In Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012). Доступно на: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf.Проверено 18.09.2016).; Smirnov AV, Shilov EM, Dobronravov VA National guidelines. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. St. Petersburg: Levsha; 2012. In Russian (Смирнов А. В., Шилов Е. М., Добронравов В. А. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. СПб.: Левша: 2012).; Schwartzenberg, S., Lev EI., Sagie A., et al. The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease. Am J Cardiol 2016; 117(3): 477- 82.; Alonso A., Lopez FL., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123(25): 2946-53.; Wheeler D.S., Giugliano R.P., Rangaswami J. Anticoagulation-related nephropathy. Thromb Haemost 2016; 14(3): 461-67.; Sardar P. Chatterjee S., Herzog E., et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol 2014; 30(8): 888-97.; Schurgers L.J., Aebert H., Vermeer C., et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104(10): 3231-2.; Pankratov V., Pigarova EA, Dzeranova L. K. Vitamin K-dependent proteins: osteocalcin, the Gla-protein matrix and vnekostnye effects. Ozhirenie i Metabolizm 2013; (2): 11-8. In Russian (Панкратова Ю. В., Пигарова Е. А., Дзеранова Л. К. Витамин К-зависимые белки: остеокальцин, матриксный Gla-белок и их внекостные эффекты. Ожирение и метаболизм 2013; (2): 11 - 8).; Luo G., Ducy P., McKee MD., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386(6620): 78-81.; Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18(9): 1400-7.; Koos R., Mahnken AH., Mühlenbruch G., et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96(6): 747-9.; Weijs B., Blaauw Y., Rennenberg RJ., et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32(20): 2555-62.; Chatrou M.L., Winckers K., Hackeng TM., et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 2012; 26(4): 155-66.; Braam L.A., Hoeks AP., Brouns F., et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91(2): 373-80.; Connolly S.J., Ezekowitz MD., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.; Patel M.R., Mahaffey KW., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.; Granger C.B., Alexander JH., McMurray JJ., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.; Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-507.; Hijazi Z., Hohnloser SH., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129(9): 961-70.; Böhm M., Ezekowitz MD., Connolly SJ., et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol 2015; 65(23): 2481-93.; Sparkenbaugh E.M., Chantrathammachart P., Mickelson J., et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014; 123(11): 1747-56.; Lee I.O., Kratz MT., Schirmer SH., et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2012; 343(2): 253-7.; Preusch M.R., Ieronimakis N., Wijelath ES., et al. Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug Des Devel Ther 2015; 9: 5203-11.; Hara T., Fukuda D., Tanaka K., et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242(2): 639-46.; Landray M.J., Wheeler DC., Lip GY., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43(2): 244-53.; Brodsky S.V., Nadasdy T., Rovin BH., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80(2): 181-9.; Brodsky S.V., Collins M., Park E., et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010; 115(2): 142-6.; Fox K.A., Piccini JP., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J, 2011; 32(19): 2387-94.; Eto M., Barandiér C., Rathgeb L., et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89(7): 583-90.; Zhou, Q., Bea F., Preuschet M., al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080.; Mega J.L., Braunwald E., Wiviott SD., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.; Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33(22): 2821-30.; Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2014; 111(4): 625-33.; https://www.rpcardio.com/jour/article/view/1342

الاتاحة: https://www.rpcardio.com/jour/article/view/1342
https://doi.org/10.20996/1819-6446-2016-12-5-595-602

المؤلفون: D. Napalkov A., E. Golovenko N., Д. Напалков А., Е. Головенко Н.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 5, No 2 (2009); 79-82 ; Рациональная Фармакотерапия в Кардиологии; Vol 5, No 2 (2009); 79-82 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2009-5-2

مصطلحات موضوعية: ramipril, ACE inhibitor, arterial hypertension, albuminuria, left ventricle hypertrophy, atrial fibrillation, рамиприл, ингибитор АПФ, артериальная гипертензия, альбуминурия, гипертрофия левого желудочка, фибрилляция предсердий

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/640/663; Seeman T., Gilík J., Vondrák K. et al. Regression of left-ventricle hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens 2007;20(9):990-6.; Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90(4):2056-69.; Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829):1173-8.; Pfeffer M.A., Braunwald E., Моуё L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10):669-77.; Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.; Tu К., Mamdani M.M., Jacka R.M. et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168(5):553-7.; Pilote L., Abrahamowicz M., Rodrigues E. et al. Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect? Ann Intern Med 2004;141(2):102- 12.; Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. AIRE Study Investigators. Lancet 1993; 342(8875):821-8.; Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;349(9064):1493-97.; Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensinconverting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95(12):2643-51.; Beluzzi F., Sernesi L., Preti P. et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009;53(1):24-9.; Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). J 1982;285(6343):685- 89.; Parving H.H., Andersen A.R., Smidt U.M., Swendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1(8335):1175-9.; Björck S., Mulec H., Johnsen S.A. et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304(6823):339-43.; Parving H.H., Hommel E., Smidt U.M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988;297(6656):1086-91.; Lewis E.J., Hunsicker L.G., Bain R.P., Rohde E.D. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329(20):1456-62.; Kasiske B.L., Kalil R.S., Ma J.Z. et al. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118(2):129-38.; Weidmann P., Schneider M., Böhlen L. Therapeutic efficacy of different antihypertensive drugs inhuman diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995;10(Suppl 9):39-45.; O'Hare P., Bilbous R., Mitchell T. et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension. The ATLANTIS study group. Diabetes Care 2000;23(12):1823-9.; Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495.; Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354(9175):359-64.; Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352(9136):1252-6.; https://www.rpcardio.com/jour/article/view/640

الاتاحة: https://www.rpcardio.com/jour/article/view/640
https://doi.org/10.20996/1819-6446-2009-5-2-79-82

المؤلفون: E. Golovenko N., D. Napalkov A., V. Sulimov A., Е. Головенко Н., Д. Напалков А., В. Сулимов А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 6, No 5 (2010); 631-638 ; Рациональная Фармакотерапия в Кардиологии; Vol 6, No 5 (2010); 631-638 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2010-6-5

مصطلحات موضوعية: chronic heart failure, troponin I, myoglobin, prognosis, хроническая сердечная недостаточность, тропонин I, миоглобин, прогноз

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/957/990; https://www.rpcardio.com/jour/article/view/957/991; Missov E., Calzolari C., Pau В. Circulating Cardiac Troponin I in Severe Congestive Heart Failure. Circulation 1997; 96(9): 2953-2958.; Beltrami C.A., Finato N., Rocco M. et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89(1):151-163.; Schaper J.S., Froede R., Hein S. et al. Impairment of the myocardial ultrastructure of the cytoskeleton in dilated cardiomyopathy. Circulation 1991;83(2):504-514.; Bardy G.H., Lee K.L., Mark D.B. et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225-37.; Missov E., Calzolari C. Elevated cardiac troponin I in some patients with severe congestive heart failure [abstract]. J Mol Cell Cardiol 1995;27:A405.; NapalkovD.A., Golovenko E.N., Sulimov V.A. Prognostic value of cardiac troponins in patients with chronic heart failure. Lechashhij vrach 2009; 2: 14-16. Russian. (Напалков Д.А., Головенко Е.Н., Сулимов В.А. К вопросу о прогностической значимости уровня сердечных тропонинов у больных хронической сердечной недостаточностью. Лечащий врач 2009; 2: 14-16); Del Carlo C.H., O'Connor C.M. Cardiac troponins in congestive heart failure. Am Heart J 1999;138(4 Pt 1):646-53.; https://www.rpcardio.com/jour/article/view/957

الاتاحة: https://www.rpcardio.com/jour/article/view/957
https://doi.org/10.20996/1819-6446-2010-6-5-631-638

المؤلفون: D. NAPALKOV A., A. SOKOLOVA A., E. SON A., S. BELOUSOV R., V. OSADCHAYA A., A. LAVROVA I., A. LENKOVSKAYA Y., A. SHOIKHET S., I. TSAREV L., Д. НАПАЛКОВ А., А. СОКОЛОВА А., Е. СОН А., С. БЕЛОУСОВ Р., В. ОСАДЧАЯ А., А. ЛАВРОВА И., А. ЛЕНКОВСКАЯ Ю., А. ШОЙХЕТ С., И. ЦАРЕВ Л.

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2016); 15-17 ; Медицинский Совет; № 11 (2016); 15-17 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-11

مصطلحات موضوعية: cryptogenic stroke, etiology, clinical case, thrombophilia, криптогенный инсульт, этиология, клинический случай, тромбофилия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1533/1489; Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and longterm survival in ischemic stroke subtypes: a population-based study. Stroke, 2001, 32(12): 2735-2740.; Lee BI, Nam HS, Heo JH et al. Yonsei Stroke Team. Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis, 2001, 12(3): 145-151.; Sacco RL, Ellenberg JH, Mohr JP et al. Infarcts of undetermined cause: the NINCDS stroke data bank. Ann Neurol, 1989, 25(4): 382-90.; King A. Atrial fibrillation: could subclinical AF be a missing link in the etiology of cryptogenic stroke? Nat Rev Cardiol, 2012, 9(3): 126.; Ntaios G, Papavasileiou V, Milionis H, Marakitsis K, Vemmou A, Koroboki E, Manios E, Spengos K, Michel P, Vemmos K. Embolic strokes of undetermined source in the Athens Stroke Registry: An Outcome analysis. Stroke, 2015, 46(8): 2087-2093.; Jaffre A, Ruidavets JB, Nasr N, Guidolin B, Ferrieres J, Larrue V. Tobacco Use and Cryptogenic Stroke in Young Adults. Jour Stroke and Cer Dis, 2015, 24(12): 2694=2700.; Aradji AA, Sawaya HR, Sawaya RA. Gene mutations and stroke in the young adult. Jour Stroke Cer Dis, 2014, 23 (10): 2554-2558.; https://www.med-sovet.pro/jour/article/view/1533

الاتاحة: https://www.med-sovet.pro/jour/article/view/1533
https://doi.org/10.21518/2079-701X-2016-11-15-17

المؤلفون: Д. Напалков А., А. Соколова А.

المصدر: Meditsinskiy sovet = Medical Council; № 5 (2016); 10-12 ; Медицинский Совет; № 5 (2016); 10-12 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-05

مصطلحات موضوعية: антикоагулянтная терапия, фибрилляция предсердий, апиксабан

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1316/1276; Wolf PA, Abbott RD, Kannel WB. AF as an independent risk factor for stroke: the Framingham Study. Stroke, 1991, 22: 983-988.; Ng KH, Hart RG, Eikelboom JW. Anticoagulation in patients aged ≥ 75 years with atrial fibrillation: role of novel oral anticoagulants. Cardiol Ther, 2013, 2: 135-149.; Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with AF. N Engl J Med, 2009, 361: 1139-51.; Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med, 2011, 365: 883-91.; Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with AF. N Engl J Med. 2011, 365: 981-92.; Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Eur Heart J, 2010, 31: 2369-2429.; Diener H-C. The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation. Thromb Hemost, 2013, 110: 493-495.; Ntaios G, Papavasileiou V, Diener H-C, Mararitsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke, 2012, 43: 3298-3304.; Tepper P, Mardekian J, Masseria K, Horblyuk R, Kamble S, Hamilton M, Abdulsattar Y, Petkun Y, Lip GYH. Real-world comparison of inpatients bleeding risk, bleeding-related hospitalization rates and costs among non-valvular atrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or swithcers from warfarin. J Am Coll Cardiol, 2016, 67 (13_S): 662-662. doi:10.1016/S0735- 1097(16)30663-5.; https://www.med-sovet.pro/jour/article/view/1316

الاتاحة: https://www.med-sovet.pro/jour/article/view/1316
https://doi.org/10.21518/2079-701X-2016-05-10-12